Last reviewed · How we verify

Continuation of somatostatin analogues

Australasian Gastro-Intestinal Trials Group · Phase 2 active Small molecule

Continuation of somatostatin analogues is a Small molecule drug developed by Australasian Gastro-Intestinal Trials Group. It is currently in Phase 2 development. Also known as: SSA continuation.

At a glance

Generic nameContinuation of somatostatin analogues
Also known asSSA continuation
SponsorAustralasian Gastro-Intestinal Trials Group
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Continuation of somatostatin analogues

What is Continuation of somatostatin analogues?

Continuation of somatostatin analogues is a Small molecule drug developed by Australasian Gastro-Intestinal Trials Group.

Who makes Continuation of somatostatin analogues?

Continuation of somatostatin analogues is developed by Australasian Gastro-Intestinal Trials Group (see full Australasian Gastro-Intestinal Trials Group pipeline at /company/australasian-gastro-intestinal-trials-group).

Is Continuation of somatostatin analogues also known as anything else?

Continuation of somatostatin analogues is also known as SSA continuation.

What development phase is Continuation of somatostatin analogues in?

Continuation of somatostatin analogues is in Phase 2.

Related